Tiger Brokers

BUZZ-Immuneering rises as quarterly loss comes in below estimates

Reuters
Mar 06
BUZZ-Immuneering rises as quarterly loss comes in below estimates

** Shares of therapy developer Immuneering IMRX.O rise 2.6% to $5.01 premarket

** Co reports Q4 adj. loss of 18 cents/shr vs analysts’ average estimate of 31 cents/shr – data compiled by LSEG

** Co says cash runway expected to fund operations into 2029

** IMRX says expanded pancreatic cancer cohort data on track for 1H 2026

** Dosing in mid‑stage trial of cancer drugs atebimetinib and Libtayo in lung cancer expected in 2H 2026, per co

** Shares up ~199% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10